ECAD-HFSpecialized Follow-up for High-Risk Heart Failure Patients After Hospitalization
This study aims to provide specialized follow-up treatment for high-risk heart failure patients after hospitalization, with the primary goal of reducing the number of participants experiencing all cause death or unplanned hospitalization within 6 months.
Natriuretic peptides levels to J7 and J14
+ Consultations specialized to J7 and J14
+ Phone calls in 6 months and 12 months
Cardiovascular Diseases
+ Heart Diseases
+ Heart Failure
Treatment Study
Summary
Study start date: June 10, 2013
Actual date on which the first participant was enrolled.At discharge, high-risk HF patients are selected and randomized in two groups: Control group: usual disease management according to guidelines and including first medical consultation and biological test within the 4-week time following discharge. Active group: consultations with HF specialist including biological test at weeks 1, 2 and 4 are planned in addition to usual management.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.507 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: 18 years or more consent signed Acute or decompensated heart failure with one or more of following criteria:: Discharge BNP > 350 pg/ml or NTproBNP > 2200 pg/ml Discharge serum creatinine ≥ 180µM Discharge systolic blood pressure ≤ 110mmHg Previous hospitalisation for acute heart failure < 6 months Exclusion Criteria: acute coronary syndrome, acute myocarditis, isolated right HF, transient HF, planned cardiac surgery, high risk of short-term non-cardiac death, planned management within rehabilitation center/HF clinic at discharge
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
Active ComparatorStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Service de Cardiologie - Hopital Lariboisière
Paris, FranceOpen Service de Cardiologie - Hopital Lariboisière in Google Maps